Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

Summary

In this pilot and feasibility study, the investigators will enroll patients with frequent symptomatic episodes of atrial fibrillation (AF) in a cross-over study testing two different classes of anti arrhythmic drugs (AADs). This pilot and feasibility study will provide preliminary data for a larger study in which the investigators will test the hypothesis that a common AF genetic risk allele modulates response to different AADs.

Timeline

Start

2020-12-31

Primary completion

2026-06-30

Completion

2026-06-30

Drugs

Indications